生命科学资讯

Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering

Boehringer axes inhaled gene therapy after viewing cystic fibrosis data

Unlocking health data

Sequence to Substance: Making the mRNA Therapeutic

Compass, with Phase 3 hits, ready to take psilocybin to the FDA

10x Genomics (TXG) Is Down 5.4% After Shelf Offer Filing And Cautious 2026 Outlook What's Changed - simplywall.st

FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher

Ocular claims a win with eye drug data even as shares sink

Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux

A single-cell time-series atlas of endothelial cell embryonic development

Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Cyrano noses toward pivotal trial after midphase smell loss win

Human organoid mimics cancer-induced cachexia

Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters

Compass Pathways soars on second Phase 3 depression hit

Compass nears NDA as psilocybin scores again in depression

Biggest gainers and losers for Feb. 9-13, 2026

DRfold2 is a deep learning-based tool that enables efficient and accurate RNA structure prediction

More drugmakers are turning to cancer combos. Will it help patients live longer?